Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 3 of 3 results for nalmefene

  1. Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)

    Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in adults with alcohol dependence.

    Technology appraisal guidance
    Published
    26 November 2014
    View recommendations

    Sections for TA325

  2. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence (CG115)

    This guideline covers identifying, assessing and managing alcohol-use disorders (harmful drinking and alcohol dependence) in adults and young people aged 10 to 17 years. It aims to reduce harms (such as liver disease, heart problems, depression and anxiety) from alcohol by improving assessment and setting goals for reducing alcohol consumption.

    Clinical guideline
    Last updated
    21 October 2014
    View recommendations

    Sections for CG115

  3. Alcohol dependence: nalmefene (ESNM29)

    This evidence summary has been replaced by NICE technology appraisal guidance 325.

    Evidence summary
    Published
    17 December 2013